Thai national guideline for nuclear medicine investigation in movement disorders: Nuclear medicine society of Thailand, the neurological society of Thailand, and Thai medical physicist society collaboration

Document Type : Others

Authors

1 Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chiang Mai University Thailand

2 PET/CT and Cyclotron Center, Center for Medicine Excellence, Faculty of Medicine, Chiang Mai University Thailand

3 Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Thailand

4 Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

5 Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani Thailand

6 Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

7 Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

8 National Cyclotron and PET Centre, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand

9 Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua, 500 Taiwan (R.O.C.)

10 Division of Nuclear Medicine, Department of Radiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

11 Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

12 Chulalongkorn University Biomedical Imaging Group (CUBIG), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

13 Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

14 Center of Excellence in Cognitive Impairment and Dementia, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Abstract

Movement disorders are chronic neurological syndromes with both treatable and non-treatable causes. The top causes of movement disorders are Parkinson's disease and related disorders. Functional imaging investigations with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) images play vital roles in diagnosis and differential diagnosis to guide disease management. Since there have been new advanced imaging technologies and radiopharmaceuticals development, there is a need for up-to-date consensus guidelines. Thus, the Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and the Thai Medical Physicist Society collaborated to establish the guideline for Nuclear Medicine investigations in movement disorder for practical use in patient care. We have extensively reviewed the current practice guidelines from other related societies and good quality papers as well as our own experience in Nuclear Medicine practice in movement disorders. We also adjust for the most suitability for application in Thailand and other developing countries.

Keywords

Main Subjects

References

  1. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017; 124(8):901-5.
  2. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage. 2005; 26(3):912-21.
  3. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4.
  4. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinsonism--a prospective study. Can J Neurol Sci. 1991; 18(3):275-8.
  5. Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, et al. Canadian guideline for Parkinson disease. Cmaj. 2019; 191(36):E989-e1004.
  6. De la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012; 78(10):696-701.
  7. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601.
  8. Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019; 34(10):1464-70.
  9. Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi k. Neuroimaging: current role in detecting pre-motor Parkinson's disease. Mov Disord. 2012; 27(5):634-43.
  10. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol. 2011; 10(11):987-1001.
  11. Politis M. Neuroimaging in Parkinson disease: from research setting to clinical Nat Rev Neurol. 2014; 10(12):708-22.
  12. erardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013; 20(1):16-34.
  13. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997; 120 (Pt 12):2187-95.
  14. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990; 113 (Pt 5): 1539-52.
  15. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994; 57(3):278-84.
  16. Arbizu J, Luquin MR, Abella J, de la Fuente-Fernandez R, Fernandez-Torron R, Garcia-Solis D, et al. [Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use]. Rev Esp Med Nucl Imagen Mol. 2014; 33(4):215-26.
  17. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 2015; 30(12):1591-601.
  18. Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008; 64 Suppl 2:S81-92.
  19. Brooks DJ. Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2002; 72 Suppl 1:I10-I6.
  20. Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014; 29(14): 1758-66.
  21. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6.
  22. Mc Keith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100.
  23. Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced Parkinsonism: a review. Fundam Clin Pharmacol. 1994; 8(4):293-306.
  24. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010; 81(1):5-12.
  25. Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010; 25(5):560-9.
  26. Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. Journal of Nuclear Medicine. 2012; 53(1):154-63.
  27. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging. European journal of nuclear medicine and molecular imaging. 2010; 37(12):2436-46.
  28. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Nagren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European journal of nuclear medicine and molecular imaging. 2009; 36(12):2103-10.
  29. Waxman AD HK, Herholz K, Lewis DH, Herscovitch P, Minoshima S, Mountz JM, et al. Society of Nuclear Medicine Procedure Guideline for FDG PET Brain Imaging Version 1.0. 2009.
  30. Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. European journal of nuclear medicine and molecular imaging. 2022; 49(2):632-51.
  31. Koopmans K, Ziekenhuis M, Eshuis GS. 18F DOPA PET/CT in Neuroendocrine Tumours and in Presynaptic Dopaminergic Deficits.
  32. Chondrogiannis S, Marzola MC, Rubello D. (18)F-DOPA PET/computed tomography imaging. PET clinics. 2014; 9(3):307-21.
  33. Yang T, Wang L, Li Y, Cheng M, Jiao J, Wang Q, et al. (131)I-MIBG myocardial scintigraphy for differentiation of Parkinson's disease from multiple system atrophy or essential tremor in Chinese population. J Neurol Sci. 2017; 373:48-51.
  34. Jokinen P, Helenius H, Rauhala E, Bruck A, Eskola O, Rinne JO. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2009; 50(6): 893-9.
  35. Sun Y, Chen Z, Liu C, Tang J, Wang Y, Zhang G, et al. Phase I clinical study with different doses of (99m)Tc-TRODAT-1 in healthy adults. Ann Nucl Med. 2020; 34(3):212-9.
  36. Xu D, Zhu W, Huo L, Zhu S, Li F, Wang H. Validation of Iodine-131-meta-iodobenzyl-guanidine cardiac scintigraphy in Parkinsonism: A preliminary study. Parkinsonism Relat Disord. 2018; 50:69-73.
  37. Ziessman MD HA OMM, Janis P, Thrall MD, James H. Nuclear Medicine The Requisites 4th Edition Saunders 2013. 2013.
  38. Yeh SH, Tsai CJ, Yu TH, Chiang YH, Lin SZ, Peng NJ, et al. 99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable. Clin Nucl Med. 2022; 47(3): 201-8.
  39. Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clinical autonomic research: official journal of the Clinical Autonomic Research Society. 2012; 22(1):43-55.
  40. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012; 18(5): 494-500.
  41. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzyl-guanidine myocardial scintigraphy. J Neurol Sci. 1998; 155(1):60-7.
  42. Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci. 2000; 175(1):3-12.
  43. Jindahra P, Vejjajiva A, Witoonpanich R, Sirisriro R, Sritara C, Pulkes T. Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzyl-guanidine (MIBG) uptake (preliminary report). Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2004; 87(10):1176-81.
  44. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPET in healthy volunteers. European journal of nuclear medicine. 2000; 27(7):867-9.
  45. Yang BH GY, Wu TH. Tc-99m TRODAT-1 SPECT imaging protocol guideline. Annals of Nuclear Medicine and Molecular Imaging 2016; 29:45-53.
  46. Yin TK, Lee BF, Yang YK, Chiu NT. Differences of various region-of-interest methods for measuring dopamine transporter availability using 99mTc-TRODAT-1 SPECT. Scientific World Journal. 2014; 2014: 837439.
  47. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2001; 42(9): 1303-8.
  48. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of movement disorders. Annals of the New York Academy of Sciences. 2011; 1228: 93-108.
  49. Brajkovic L, Kostic V, Sobic-Saranovic D, Stefanova E, Jecmenica-Lukic M, Jesic A, et al. The utility of FDG-PET in the differential diagnosis of Parkinsonism. Neurological research. 2017; 39(8):675-84.
  50. Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, et al. [(18)F]FDG-PET is superior to [(123)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012; 79(13):1314-22.
  51. Meyer PT, Frings L, Rucker G, Hellwig S. (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017; 58(12):1888-98.
  52. Song IU, Ha SW, Yang YS, Chung YA. Differences in Regional Glucose Metabolism of the Brain Measured with F-18-FDG-PET in Patients with Essential Tremor According to Their Response to Beta-Blockers. Korean journal of radiology. 2015; 16(5):967-72.
  53. Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, et al. Clinical utility of FDG PET in Parkinson's disease and atypical Parkinsonism associated with dementia. European journal of nuclear medicine and molecular imaging. 2018; 45(9):1534-45.
  54. Chevalme Y-M, Montravers F, Vuillez J-P, Zanca M, Fallais C, Oustrin J, et al. FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Brazilian Archives of Biology and Technology. 2007; 50:77-90.
  55. Highlight of prescribing information F-DOPA [Internet]. 2019. Available from: https:// www.accessdata.fda.gov/ drugsatfda_docs/label/2019/200655s000lbl.pdf.
  56. Booij J, Kemp P. Dopamine transporter imaging with [123 I] FP-CIT SPECT: potential effects of drugs. European journal of nuclear medicine and molecular imaging. 2008; 35(2):424-38.
  57. Tatsch K, Någren K, Nobili F, Walker Z. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neuro-transmission SPECT using (123) I-labelled dopamine transporter ligands, version 2. 2009.
  58. Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. European journal of nuclear medicine and molecular imaging. 2011; 38(4):764-73.
  59. Linke R, Gostomzyk J, Hahn K, Tatsch K. [123 I] IPT binding to the presynaptic dopamine transporter: variation of intra-and inter observer data evaluation in parkinsonian patients and controls. European journal of nuclear medicine. 2000; 27(12):1809-12.
  60. Morton RJ, Guy MJ, Clauss R, Hinton PJ, Marshall CA, Clarke EA. Comparison of different methods of DatSCAN quantification. Nuclear medicine communications. 2005; 26(12):1139-46.
  61. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. Journal of nuclear medicine: Official publication, Society of Nuclear Medicine. 1998; 39(7):1143-8.
  62. Jacobson AF, Travin MI. Impact of medications on MIBG uptake, with specific attention to the heart: comprehensive review of the literature. Journal of Nuclear Cardiology. 2015; 22(5):980-93.
  63. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. I-123 MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. QJ Nucl Med. 2008; 52: 378-87.
  64. Skowronek C, Zange L, Lipp A. Cardiac 123I-MIBG Scintigraphy in Neurodegenerative Parkinson Syndromes: Performance and Pitfalls in Clinical Practice. Front Neurol. 2019; 10: 152.
  65. Tsujikawa K, Hasegawa Y, Yokoi S, Yasui K,Nanbu I, Yanagi T, et al. Chronological changes of 123I-MIBG myocardial scintigraphy and clinical features of Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry. 2015; 86(9):945-51.
  66. Borsatti E. PET and PET/CT-a clinical guide,EC Lin, A. Alavi (Eds.), Thieme, New York/Stuttgart (2009), 312 pages, 505 illustrations, US $79.95, ISBN: 978-1-60406-153-6. Elsevier; 2010.
  67. Tepmongkol S, Srikijvilaikul T, Vasavid P. Factors affecting bilateral temporal lobe hypometabolism on 18F-FDG PET brain scan in unilateral medial temporal lobe epilepsy. Epilepsy & Behavior. 2013; 29(2): 386-9.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 12, Issue 2
July 2024
Pages 86-107

Files

Share

How to cite

Statistics